GO
Loading...

Enter multiple symbols separated by commas

Pfizer Inc

More

  • Dollar's rampage costs companies billions: Study Monday, 15 Jun 2015 | 6:00 AM ET
    Sheets of one dollar bills run through the printing press at the Bureau of Engraving and Printing in Washington, DC.

    The market knew it would be ugly. Now, it's clear just how much havoc the strong dollar is wreaking on corporate America.

  • Wall Street firm's portfolio up 29% in 18 months Friday, 12 Jun 2015 | 2:46 PM ET
    Trader on the floor of the New York Stock Exchange.

    A portfolio by investment bank Jefferies is up 29 percent since it was created in December 2013. Here are some of the stocks...

  • Stocks that may break out while market drags Friday, 12 Jun 2015 | 11:48 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Traders are finding shorter-term opportunities amidst market drag.

  • Asian shares mostly rise on a quiet Friday, with China's Shanghai Composite index edging up to its highest close since January 2008.

  • Cramer: Massive biotech moves that make sense Thursday, 11 Jun 2015 | 6:57 PM ET
    A worker prepares a flow cell slide for a genetic sequencing machine at a Regeneron Pharmaceuticals laboratory company's headquarters in Tarrytown, New York.

    Jim Cramer discusses the huge moves that the biotech stocks have made recently—do these moves make sense for your portfolio?

  • NEW YORK, June 11- A U.S. jury on Thursday said Pfizer Inc was not responsible for birth defects in a young girl whose mother took its antidepressant Zoloft while pregnant, the second straight win for the company out of hundreds of similar lawsuits. Plaintiff Rachel Robinson claimed in her 2011 lawsuit that Pfizer failed to warn that using Zoloft during pregnancy...

  • NEW YORK, June 11- A U.S. jury on Thursday said Pfizer Inc was not responsible for birth defects in a young girl whose mother took its antidepressant Zoloft while pregnant, the second straight win for the company out of hundreds of similar lawsuits. Following a week-and-a-half long trial in state court in Philadelphia, jurors on Thursday returned a verdict for the...

  • Why a FDA nod isn't enough for Regeneron shares Wednesday, 10 Jun 2015 | 12:49 PM ET
    A technician at Regeneron Pharmaceuticals headquarters in Tarrytown, N.Y.

    Regeneron's shares sank 4 percent despite a positive Food and Drug Administration recommendation on a cholesterol drug. What gives?

  • LONDON, June 10- AstraZeneca's chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group's research operations. A spokeswoman said on Wednesday Morrison was departing to become chief executive of an unlisted venture capital-backed drugmaker in the United States,...

  • LONDON, June 10- AstraZeneca's chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group's research operations. Morrison, who joined AstraZeneca from Pfizer in 2012, has played a central role in the British drugmaker's bid to turn around its portfolio.

  • 10 drugs to hit fed budget by $50B over decade Tuesday, 9 Jun 2015 | 1:42 PM ET
    Health Care

    Ten so-called breakthrough drugs for cancers and chronic conditions will cost taxpayers big bucks.

  • A French doctor, venture capitalist and founder of biotech company Abivax, Pouletty is working with Cuba's Center for Genetic Engineering and Biotechnology to develop a therapeutic vaccine to treat chronic Hepatitis B that could be on the Asian market in two years and in Europe after that. Instead, Abivax agreed to buy vaccines at a predetermined price and pay...

  • M&A: Dealmaking like 2007 all over again? Wednesday, 3 Jun 2015 | 7:29 AM ET

    Mergers and acquisitions are close to pre-financial crisis levels for the first time in 2015, as companies search for deals again.

  • CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...

  • Pfizer gaining market share in oncology: CEO Monday, 1 Jun 2015 | 1:09 PM ET
    Ian Read, CEO of Pfizer.

    Pfizer's share of the market for certain cancer drugs has increased from 10 to 20 percent, Chairman and CEO Ian Read tells CNBC.

  • 'Viagra for women' gets push for FDA approval Monday, 1 Jun 2015 | 12:02 PM ET
    A tablet of flibanserin at Sprout Pharmaceuticals in Raleigh, N.C.

    A campaign accuses the FDA of gender bias for approving drugs to help men have sex, but none for women. The NYT reports.

  • Pfizer CEO: Ibrance drug well received by physicians Monday, 1 Jun 2015 | 11:16 AM ET
    Pfizer CEO: Ibrance drug well received by physicians

    Pfizer CEO Ian Read, discusses the PALOMA-3 trial for its oncology treatment Ibrance to treat breast cancer, drug pricing and competition in the pharmaceutical industry.

  • Trading pharma: 5 plays on Bristol's rough day Friday, 29 May 2015 | 6:47 PM ET
    Bristol-Myers Squibb R&D headquarters.

    Bristol-Myers Squibb's battering after a disappointing drug trial serves as a buying opportunity, "Fast Money" traders said.

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed lower on the last trading day of the month, as investors digested data and remained cautious on continued concerns about Greece.